JB Chemicals & Pharmaceuticals Limited — PPTs, 07-11-2024: Investor Presentation

JB Chemicals & Pharmaceuticals reported a revenue increase of 13% to ₹1,001 crore for Q2 FY25, maintaining high EBITDA margins at 28%. Domestic formulations grew significantly, driving overall performance. The international business also showed growth, though the CDMO segment experienced seasonal challenges. The company emphasized its strong product portfolio and commitment to sustainable growth, while managing costs effectively. Robust capital efficiency and debt reduction were highlighted, reinforcing JB Pharma's growth trajectory.